Contribution of Clinical Neuroimaging to the Understanding of the Pharmacology of Methylphenidate.

Related Articles

Contribution of Clinical Neuroimaging to the Understanding of the Pharmacology of Methylphenidate.

Trends Pharmacol Sci. 2017 Apr 24;:

Authors: Zimmer L

Abstract
Methylphenidate (MPH) is currently the most widely used molecule in the pharmacologic treatment of attention-deficit hyperactivity disorder (ADHD). Although experience of its application now extends over several decades, its psychotropic nature, prolonged use in children, and chemical relation to amphetamines still raise doubts in the minds of prescribers and the families of the patients. Brain imaging has shed considerable light on the neuropharmacology of MPH. The two main in vivo neuroimaging techniques are positron-emission tomography (PET) and magnetic resonance imaging (MRI), and these can be applied in both animal models and humans. The present review seeks to show how human molecular and functional imaging has contributed to determining not only the molecular targets of MPH, and the action kinetics of the various pharmaceutical forms available, but also the connectivity and brain networks activated by treatment. We also discuss the perspectives opened up by new hybrid PET-MRI techniques that enable multimodal tracking of the impact of methylphenidate on neurotransmission.

PMID: 28450072 [PubMed – as supplied by publisher]

via https://www.ncbi.nlm.nih.gov/pubmed/28450072?dopt=Abstract